WO2014194435A3 - Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component. - Google Patents

Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component. Download PDF

Info

Publication number
WO2014194435A3
WO2014194435A3 PCT/CH2014/000075 CH2014000075W WO2014194435A3 WO 2014194435 A3 WO2014194435 A3 WO 2014194435A3 CH 2014000075 W CH2014000075 W CH 2014000075W WO 2014194435 A3 WO2014194435 A3 WO 2014194435A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
regimen
activating
administering
applying
Prior art date
Application number
PCT/CH2014/000075
Other languages
English (en)
French (fr)
Other versions
WO2014194435A2 (en
Inventor
Farhad HAFEZI
Olivier RICHOZ
Original Assignee
Hafezi Farhad
Richoz Olivier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CH10682013 priority Critical
Priority to CH1068/13 priority
Application filed by Hafezi Farhad, Richoz Olivier filed Critical Hafezi Farhad
Publication of WO2014194435A2 publication Critical patent/WO2014194435A2/en
Publication of WO2014194435A3 publication Critical patent/WO2014194435A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0026Ophthalmic product dispenser attachments to facilitate positioning near the eye
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F9/00825Methods or devices for eye surgery using laser for photodisruption
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08Radiation
    • A61L2/088Radiation using a photocatalyst or photosensitiser
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0601Apparatus for use inside the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0613Apparatus adapted for a specific treatment
    • A61N5/062Photodynamic therapy, i.e. excitation of an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0613Apparatus adapted for a specific treatment
    • A61N5/0624Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00017Electrical control of surgical instruments
    • A61B2017/00022Sensing or detecting at the treatment site
    • A61B2017/00084Temperature
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/36Image-producing devices or illumination devices not otherwise provided for
    • A61B90/37Surgical systems with images on a monitor during operation
    • A61B2090/373Surgical systems with images on a monitor during operation using light, e.g. by using optical scanners
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F2009/00842Permanent Structural Change [PSC] in index of refraction; Limit between ablation and plasma ignition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N2005/002Cooling systems
    • A61N2005/005Cooling systems for cooling the radiator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0626Monitoring, verifying, controlling systems and methods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0626Monitoring, verifying, controlling systems and methods
    • A61N2005/0627Dose monitoring systems and methods
    • A61N2005/0628Dose monitoring systems and methods including a radiation sensor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/063Radiation therapy using light comprising light transmitting means, e.g. optical fibres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/065Light sources therefor
    • A61N2005/0651Diodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0658Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661Radiation therapy using light characterised by the wavelength of light used ultra-violet
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0658Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662Visible light
    • A61N2005/0663Coloured light
PCT/CH2014/000075 2013-06-05 2014-06-04 Method of applying a composition and pharmaceutical composition with a regimen of administering it WO2014194435A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CH10682013 2013-06-05
CH1068/13 2013-06-05

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14/895,288 US20160120979A1 (en) 2013-06-05 2014-06-04 Method of applying a composition and pharmaceutical composition with a regimen of administering it
CN201480044261.1A CN105579063A (zh) 2013-06-05 2014-06-04 包括光活化活性组分的施用组合物的方法和具有给予药物组合物的方案的药物组合物
JP2016517105A JP2016520623A (ja) 2013-06-05 2014-06-04 活性成分を光活性化することを含む、組成物を適用する方法および投与されるレジメンを有する医薬組成物
KR1020157037180A KR20160068701A (ko) 2013-06-05 2014-06-04 유효성분을 광활성화시키는 것을 포함하는 조성물을 도포하는 방법 및 투여 방식을 가진 약제학적 조성물
EP14733966.7A EP3003375A2 (en) 2013-06-05 2014-06-04 Method of applying a composition and pharmaceutical composition with a regimen of administering it
BR112015030233A BR112015030233A2 (pt) 2013-06-05 2014-06-04 método de aplicação de uma composição e composição farmacêutica com um regime de administração da mesma
ZA2015/08454A ZA201508454B (en) 2013-06-05 2015-11-16 Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component
HK16111318.4A HK1223029A1 (zh) 2013-06-05 2016-09-27 施用組合物的方法和具有給予藥物組合物的方案的藥物組合物

Publications (2)

Publication Number Publication Date
WO2014194435A2 WO2014194435A2 (en) 2014-12-11
WO2014194435A3 true WO2014194435A3 (en) 2015-02-05

Family

ID=51032861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2014/000075 WO2014194435A2 (en) 2013-06-05 2014-06-04 Method of applying a composition and pharmaceutical composition with a regimen of administering it

Country Status (9)

Country Link
US (1) US20160120979A1 (un)
EP (1) EP3003375A2 (un)
JP (1) JP2016520623A (un)
KR (1) KR20160068701A (un)
CN (1) CN105579063A (un)
BR (1) BR112015030233A2 (un)
HK (1) HK1223029A1 (un)
WO (1) WO2014194435A2 (un)
ZA (1) ZA201508454B (un)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101894150B1 (ko) * 2016-11-15 2018-08-31 포항공과대학교 산학협력단 다광자 특성을 이용한 안과용 진단 및 치료장치
WO2018169967A1 (en) * 2017-03-14 2018-09-20 Allergan, Inc. Acorafloxacin in treating ocular infections

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153962A1 (en) * 2002-02-11 2003-08-14 Cumbie William Emmett Method for the prevention and treatment of skin and nail infections
JP2008079510A (ja) * 2006-09-26 2008-04-10 Yamaguchi Univ 薬剤耐性病原性微生物の薬剤感受性増強方法、および高度薬剤耐性菌の出現予防方法
WO2009042159A1 (en) * 2007-09-24 2009-04-02 The Johns Hopkins University Wearable photoactivator for ocular therapeutic applications and use thereof
US20110054305A1 (en) * 2009-08-30 2011-03-03 Stephen Eliot Zweig Photon upconverting implantable medical devices
WO2012122210A1 (en) * 2011-03-07 2012-09-13 The Trustees Of Columbia University In The City Of New York Apparatus, method, and system for selectively affecting and/or killing bacteria

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102645A (en) * 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
CA2215978A1 (en) * 1995-04-04 1996-10-10 Wound Healing Of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US5866295A (en) * 1997-03-07 1999-02-02 Clariant Finance (Bvi) Limited Photosensitive quinolone compounds and a process of preparation
CN1148184C (zh) * 1999-10-28 2004-05-05 上海复旦张江生物医药股份有限公司 光动力治疗肿瘤药物组合物
US6951630B2 (en) * 2001-08-16 2005-10-04 Ceramoptec Industries, Inc. Method and substance for obtaining surfaces with antimicrobial properties
ES2320430T3 (es) * 2001-08-22 2009-05-22 Montana State University-Bozeman Porfirinas con secciones eficaces de absorcion multifotonica mejoradas para terapia fotodinamica.
WO2003094767A1 (en) * 2002-03-25 2003-11-20 The General Hospital Corporation Methods of adjuvant photodynamic therapy to enhance radiation sensitization
GB0323699D0 (en) * 2003-10-09 2003-11-12 Univ London Use of photosensitisation
JP5967935B2 (ja) * 2008-04-04 2016-08-10 イミュノライト・エルエルシー insituでのフォトバイオモデュレーションのための非侵襲性システムおよび方法
CN101612149A (zh) * 2009-07-28 2009-12-30 陈志龙 血卟啉单甲醚在医药领域的新用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153962A1 (en) * 2002-02-11 2003-08-14 Cumbie William Emmett Method for the prevention and treatment of skin and nail infections
JP2008079510A (ja) * 2006-09-26 2008-04-10 Yamaguchi Univ 薬剤耐性病原性微生物の薬剤感受性増強方法、および高度薬剤耐性菌の出現予防方法
WO2009042159A1 (en) * 2007-09-24 2009-04-02 The Johns Hopkins University Wearable photoactivator for ocular therapeutic applications and use thereof
US20110054305A1 (en) * 2009-08-30 2011-03-03 Stephen Eliot Zweig Photon upconverting implantable medical devices
WO2012122210A1 (en) * 2011-03-07 2012-09-13 The Trustees Of Columbia University In The City Of New York Apparatus, method, and system for selectively affecting and/or killing bacteria

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BECERRA M C ET AL: "Light effect and reactive oxygen species in the action of ciprofloxacin on Staphylococcus aureus", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, ELSEVIER SCIENCE S.A., BASEL, CH, vol. 76, no. 1-3, 25 October 2004 (2004-10-25), pages 13 - 18, XP004602797, ISSN: 1011-1344, DOI: 10.1016/J.JPHOTOBIOL.2004.06.003 *
DATABASE WPI Week 200835, Derwent World Patents Index; AN 2008-F14405, XP002728474 *
HIRO YASUKAWA ET AL: "Photomanipulation of antibiotic susceptibility and biofilm formation of Escherichia coli heterologously expressing photoactivated adenylyl cyclase", THE JOURNAL OF GENERAL AND APPLIED MICROBIOLOGY, vol. 58, no. 3, 1 January 2012 (2012-01-01), pages 183 - 190, XP055134741, ISSN: 0022-1260, DOI: 10.2323/jgam.58.183 *
YANAGAWA T ET AL: "Photodynamic bactericidal effect of tetracycline on methicillin resistant Staphylococcus aureus", LASERS IN THE LIFE SCIENCE, HARWOOD ACADEMIC PUBLISHERS, GB, vol. 6, no. 3, 1 January 1994 (1994-01-01), pages 187 - 196, XP008171251, ISSN: 0886-0467 *

Also Published As

Publication number Publication date
HK1223029A1 (zh) 2017-07-21
CN105579063A (zh) 2016-05-11
WO2014194435A2 (en) 2014-12-11
BR112015030233A2 (pt) 2017-07-25
ZA201508454B (en) 2017-02-22
EP3003375A2 (en) 2016-04-13
JP2016520623A (ja) 2016-07-14
KR20160068701A (ko) 2016-06-15
US20160120979A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
MX2014000648A (es) Compuestos heterociclicos y sus usos.
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
WO2014194254A8 (en) Treatment of cancers using pi3 kinase isoform modulators
MX2014009219A (es) Compuestos de purinona como inhibidores de quinasas.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
MX2016005482A (es) Formas de dosificacion granuladas disuasivas del abuso de liberacion inmediata.
WO2014158811A8 (en) Newcastle disease viruses and uses thereof
MX2015010880A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
TW201431851A (en) Bruton's tyrosine kinase inhibitors
HK1217330A1 (zh) -苯基-氨甲酰衍生物及其作爲藥物用於治療乙型肝炎的用途
MX2015017964A (es) Inhibidores de bromodominio.
MX2012014231A (es) Metodos de terapia combinada para tratar enfermedades proliferativas.
MX2015006168A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas.
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
SI3023415T1 (en) Inhibitors of histone demethylases
TW201440767A (en) Androgen receptor modulator and uses thereof
EA028085B1 (ru) Карбаматные соединения и их применение
WO2015095811A8 (en) Combination therapy with neoantigen vaccine
CL2015001437A1 (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
CL2016001936A1 (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CN105189479A (zh) 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
MX2016007826A (es) Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco.
IL236221A (en) Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480044261.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14733966

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2014733966

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14895288

Country of ref document: US

ENP Entry into the national phase in:

Ref document number: 2016517105

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015030233

Country of ref document: BR

ENP Entry into the national phase in:

Ref document number: 20157037180

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 112015030233

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20151202